3 High Growth Companies Insiders Are Betting On
Over the last 7 days, the United States market has experienced a slight drop of 1.5%, yet it has shown resilience with a 13% rise over the past year and an expected annual earnings growth of 17%. In this environment, companies with high insider ownership can be particularly appealing as insiders' confidence in their company's potential often aligns with strong growth prospects.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 14.2% | 68.4% |
| Standard Nuclear (STDN) | 18.8% | 61.3% |
| Precigen (PGEN) | 11.7% | 55.4% |
| Nu Holdings (NU) | 22.8% | 21.8% |
| Karman Holdings (KRMN) | 14.4% | 54% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 16.9% | 23.2% |
| Carlyle Group (CG) | 27.4% | 20.5% |
| Almonty Industries (ALM) | 10.8% | 38% |
Let's explore several standout options from the results in the screener.
ImmunityBio (IBRX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ImmunityBio, Inc. is a biotechnology company that innovates, develops, and commercializes next-generation immunotherapies aimed at activating the immune system for durable protection against cancer and infectious diseases, with a market cap of $8.38 billion.
Operations: The company's revenue segment focuses on generating $165.79 million from its efforts in advancing and bringing to market cutting-edge immunotherapies.
Insider Ownership: 27.9%
Return On Equity Forecast: N/A (2029 estimate)
ImmunityBio is trading significantly below its estimated fair value, with analysts expecting a 52.3% price increase. Revenue is forecast to grow at 49.7% per year, outpacing the market significantly, and profitability is anticipated within three years. Despite recent index exclusions, the company's strategic appointments and global regulatory approvals for ANKTIVA® enhance its growth potential in immunotherapy markets. However, financial losses remain substantial despite rising revenues.
- Click to explore a detailed breakdown of our findings in ImmunityBio's earnings growth report.
- The valuation report we've compiled suggests that ImmunityBio's current price could be quite moderate.
Hinge Health (HNGE)
Simply Wall St Growth Rating: ★★★★★★
Overview: Hinge Health, Inc. develops technology to scale and automate healthcare delivery, with a market cap of $7.15 billion.
Operations: Hinge Health generates revenue primarily from its Healthcare Software segment, which accounts for $720.06 million.
Insider Ownership: 15.3%
Return On Equity Forecast: 20% (2029 estimate)
Hinge Health demonstrates strong growth potential with earnings forecasted to grow 27.6% annually, outpacing the US market. Recent profitability and a significant revenue increase to US$212.82 million in Q2 2026 underscore its upward trajectory. Despite limited insider buying recently, the company is trading at a substantial discount to its fair value and has expanded its buyback program by US$300 million, enhancing shareholder value. Additionally, inclusion in multiple Russell indices supports investor confidence.
- Delve into the full analysis future growth report here for a deeper understanding of Hinge Health.
- According our valuation report, there's an indication that Hinge Health's share price might be on the expensive side.
Pershing Square (PS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pershing Square Inc. operates as an alternative asset manager with a market cap of $15.07 billion.
Operations: The company's revenue primarily comes from its asset management segment, generating $768.71 million.
Insider Ownership: 27.6%
Return On Equity Forecast: 40% (2029 estimate)
Pershing Square Inc. shows potential with forecasted annual earnings growth of 68.9%, significantly outpacing the US market's 17.2%. Despite a recent quarterly net loss of US$42.7 million, its first cash dividend since IPO and high insider ownership may indicate confidence in long-term prospects. However, revenue growth is expected to lag behind the market at just 0.6% annually, which could temper investor enthusiasm for immediate returns despite a projected high return on equity of 39.5%.
- Navigate through the intricacies of Pershing Square with our comprehensive analyst estimates report here.
- The analysis detailed in our Pershing Square valuation report hints at an inflated share price compared to its estimated value.
Key Takeaways
- Dive into all 182 of the Fast Growing US Companies With High Insider Ownership we have identified here.
- Interested In Other Possibilities? Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com